Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Tharimmune ( (THAR) ) is now available.
On June 13, 2025, Tharimmune, Inc. entered into a securities purchase agreement with accredited investors for a private placement of common stock and warrants. The transaction, expected to close on June 20, 2025, aims to raise approximately $2.5 million in gross proceeds, which will be used for clinical development and working capital.
The most recent analyst rating on (THAR) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Tharimmune stock, see the THAR Stock Forecast page.
More about Tharimmune
Average Trading Volume: 130,294
Technical Sentiment Signal: Sell
See more insights into THAR stock on TipRanks’ Stock Analysis page.